Join Edgewise Chief Scientific Officer and Chief Medical Officer to learn more about the clinical development program for EDG-5506, a myosin modulator, in Becker and Duchenne muscular dystrophies. The presentation […]
Moving from Bench to Clinic to Deliver a Potentially Transformative Therapy for Duchenne Muscular Dystrophy Join us for a Fireside Chat discussing Dyne’s Phase 1/2 clinical trial, DELIVER, evaluating DYNE-251 […]
Pratteln, Switzerland, and Rockville, MD, USA, October 27, 2022 – Santhera Pharmaceuticals (SIX: SANN) and ReveraGen BioPharma, Inc announce that they have completed the rolling submission of a new drug […]
Consistent and frequent physical therapy is one of the few currently available treatments that’s been proven to provide benefits at all ages with the potential to delay disease progression. However, traditional […]
We are pleased to announce that six sites are open for enrollment for the Canyon trial for individuals living with Becker Muscular Dystrophy! Canyon is a Phase 2 trial of […]
See full PRESS RELEASE: https://www.globenewswire.com/news-release/2022/10/13/2534198/0/en/PepGen-Presents-Data-from-its-Duchenne-Muscular-Dystrophy-Program-at-World-Muscle-Society-Congress.html
Dyne Therapeutics, who received early funding from CureDuchenne, presented promising preclinical data from their Duchenne Exon 51 and 53 programs at the World Muscle Society Congress. This was Dyne’s first […]
Community. Support. Knowledge. These are the things families and professionals worldwide seek – especially when faced with a rare disease like Duchenne. That’s why, in partnership with Duchenne Hungary, CureDuchenne […]
Edgewise Therapeutics, which received early funding from CureDuchenne, announced positive 6-month interim results from the ongoing ARCH study, an open label study of EDG-5506 in adults with Becker muscular dystrophy. Edgewise […]
